Reinduction and Maintenance of Second or Third Remissions in Children With Acute Lymphoblastic and Acute Undifferentiated Leukemia

A Phase II Study of Oral Fludarabine Phosphate in Patients with Previously Untreated B-cell Chronic Lymphocytic Leukemia

A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma

A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma (RADAR)

A Clinical Trial of MOPP/ABV Hybrid versus Alternating MOPP/ABVD for Advanced or Recurrent Hodgkin's Disease

Treatment of Advanced Hodgkin's Disease a Randomized Phase III Trial Comparing ABVD versus MOPP/ABV Hybrid

A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease

A Randomized Phase III Trial of ABVD Versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease

BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma

A Randomized Comparison of Deoxycoformycin versus Alpha Interferon in Previously Untreated Patients With Hairy Cell Leukemia

A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+B-Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant)for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk International Classification Prognostic Groups

A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation.

A Multi-centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone and Rituximab (BCVP-R) for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment

A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

A Comparison of Standard BACOP With Escalated BACOP in Patients With Poor Prognosis Non-Hodgkin's Lymphoma

Phase I/II Study of Chemotherapy Intensification for Patients With Poor Prognosis Advanced Stage Aggressive histology Lymphoma: VACOP-B Plus Etoposide and Cyclophosphamide With RhuGM-CSF (VACOP-B/EC/CSF)

A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
HEMATOLOGIC	AL1	2	0	1	1
HEMATOLOGIC	CL2	128	0	0	0
HEMATOLOGIC	HD11	Open Trial	31	37	60
HEMATOLOGIC	HD12	Open Trial	4	10	13
HEMATOLOGIC	HD4	332	0	1	1
HEMATOLOGIC	HD5	52	0	35	35
HEMATOLOGIC	HD6	405	0	125	125
HEMATOLOGIC	HD7	103	1	2	3
HEMATOLOGIC	HD8	43	12	29	29
HEMATOLOGIC	HL1	39	0	1	1
HEMATOLOGIC	LY11	122	4	14	15
HEMATOLOGIC	LY12	619	306	312	395
HEMATOLOGIC	LY13	95	45	19	60
HEMATOLOGIC	LY16	48	24	14	31
HEMATOLOGIC	LY17	129	35	70	78
HEMATOLOGIC	LY18	Open Trial	0	21	21
HEMATOLOGIC	LY3	298	0	1	1
HEMATOLOGIC	LY4	28	0	15	15
HEMATOLOGIC	MDC1	34	1	8	9
HEMATOLOGIC	MY10	332	0	0	0

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
HEMATOLOGIC	AL1	2	0	0
HEMATOLOGIC	CL2	128	0	0
HEMATOLOGIC	HD11	Open Trial	0	0
HEMATOLOGIC	HD12	Open Trial	0	0
HEMATOLOGIC	HD4	332	0	0
HEMATOLOGIC	HD5	52	0	0
HEMATOLOGIC	HD6	405	0	0
HEMATOLOGIC	HD7	103	0	0
HEMATOLOGIC	HD8	43	0	0
HEMATOLOGIC	HL1	39	0	0
HEMATOLOGIC	LY11	122	0	0
HEMATOLOGIC	LY12	619	8	163
HEMATOLOGIC	LY13	95	1	1
HEMATOLOGIC	LY16	48	1	4
HEMATOLOGIC	LY17	129	1	1
HEMATOLOGIC	LY18	Open Trial	0	0
HEMATOLOGIC	LY3	298	0	0
HEMATOLOGIC	LY4	28	0	0
HEMATOLOGIC	MDC1	34	0	0
HEMATOLOGIC	MY10	332	0	0

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
HEMATOLOGIC	AL1	2	1	0	1	0	1	1	0	0
HEMATOLOGIC	CL2	128	0	0	0	0	0	0	0	0
HEMATOLOGIC	HD11	Open Trial	10	0	0	0	5	13	0	0
HEMATOLOGIC	HD12	Open Trial	4	0	0	0	0	4	0	0
HEMATOLOGIC	HD4	332	0	0	0	0	0	0	0	0
HEMATOLOGIC	HD5	52	0	0	0	0	0	0	0	0
HEMATOLOGIC	HD6	405	0	0	0	0	0	0	0	0
HEMATOLOGIC	HD7	103	0	0	0	0	0	0	0	0
HEMATOLOGIC	HD8	43	0	0	0	0	0	0	0	0
HEMATOLOGIC	HL1	39	0	0	0	0	0	0	0	0
HEMATOLOGIC	LY11	122	0	0	0	0	0	0	0	0
HEMATOLOGIC	LY12	619	0	0	1	0	0	0	0	0
HEMATOLOGIC	LY13	95	0	0	0	0	0	0	0	0
HEMATOLOGIC	LY16	48	0	0	0	0	0	0	0	0
HEMATOLOGIC	LY17	129	93	0	0	0	96	92	0	0
HEMATOLOGIC	LY18	Open Trial	16	0	0	0	18	18	0	0
HEMATOLOGIC	LY3	298	0	0	0	0	0	0	0	0
HEMATOLOGIC	LY4	28	0	0	0	0	0	0	0	0
HEMATOLOGIC	MDC1	34	16	0	0	0	0	0	0	0
HEMATOLOGIC	MY10	332	0	0	0	0	0	0	0	0